Diaphyseal Tuberculosis in Sickle Cell Anemia: A Rare but Critical Diagnosis

When a patient with sickle cell anemia presents with persistent bone pain, the differential diagnosis is broad—and often life-altering. While osteomyelitis caused by Salmonella or Staphylococcus species is a well-documented complication of sickle cell disease (SCD), a far rarer but equally devastating possibility is diaphyseal tuberculosis (TB) of the long bones. A recent case report published in SCIRP Open Access highlights this unusual intersection of two distinct pathologies, offering critical insights for clinicians navigating complex presentations in high-risk populations.

Understanding the Case: A Convergence of Two Diseases

The case report describes a patient with homozygous sickle cell anemia (HbSS), the most severe form of SCD, who developed chronic pain and swelling in the left tibia. Initial imaging suggested a bone infection, but standard cultures for common pathogens returned negative. Further investigation—including a bone biopsy and polymerase chain reaction (PCR) testing—revealed Mycobacterium tuberculosis, the bacterium responsible for TB. The infection was localized to the diaphysis (the shaft of the tibia), a site rarely affected by TB, which more commonly targets the spine or joints.

This case underscores a critical clinical challenge: the overlap of symptoms between sickle cell-related bone complications and atypical infections. Both conditions can cause chronic pain, fever and localized swelling, but their treatments differ dramatically. Misdiagnosis or delayed diagnosis can lead to irreversible bone damage, systemic spread of infection, or even death.

Why Diaphyseal Tuberculosis Is So Rare—and So Dangerous

Tuberculosis of the bone, or osteoarticular TB, accounts for roughly 1–3% of all TB cases. Within this subset, diaphyseal involvement is exceptionally uncommon. The diaphysis is typically resistant to TB due to its limited blood supply compared to the metaphysis (the growing ends of bones) or joints. However, in patients with sickle cell anemia, the risk of unusual infections—including TB—is elevated due to:

• Chronic hemolysis and vascular occlusion: Repeated sickling crises damage bone marrow and blood vessels, creating hypoxic environments where M. Tuberculosis can thrive.
• Functional asplenia: By early childhood, most patients with SCD lose splenic function due to repeated infarctions, impairing their ability to clear encapsulated bacteria like M. Tuberculosis.
• Immunosuppression: SCD is associated with immune dysregulation, including defects in neutrophil and macrophage function, which increase susceptibility to intracellular pathogens.

A study published in SCIRP found that among 6 patients with sickle cell anemia and chronic bone infections, multiple lesions were present in 10 cases, and long bones were affected in 90% of instances. While this study did not specifically address TB, it highlights the vulnerability of long bones in SCD—a vulnerability that may extend to atypical pathogens like M. Tuberculosis.

Diagnostic Dilemmas: Distinguishing TB from Other Bone Infections

In patients with SCD, bone pain is often attributed to avascular necrosis (AVN), sickle cell crises, or osteomyelitis caused by Salmonella or Staphylococcus. However, the case report emphasizes the importance of considering TB in the differential diagnosis, particularly when:

• Standard cultures are negative: Common bacterial pathogens may not grow in routine cultures, especially if the patient has received prior antibiotics.
• Imaging shows atypical patterns: Diaphyseal TB may present as a lytic lesion with sequestrum (a piece of dead bone) or periosteal reaction, which can mimic chronic osteomyelitis or even malignancy.
• There is a history of TB exposure or risk factors: Patients with SCD who live in or travel to TB-endemic regions, or who have close contact with active TB cases, are at higher risk.

The gold standard for diagnosing osteoarticular TB is histopathological examination and microbiological confirmation, often requiring a bone biopsy. PCR testing can provide faster results than traditional cultures, which may take weeks to grow M. Tuberculosis.

Treatment Challenges: Balancing Efficacy and Safety

Managing diaphyseal TB in a patient with SCD is complex due to:

1. Drug interactions and toxicity: First-line anti-TB medications like isoniazid, rifampin, pyrazinamide, and ethambutol can interact with medications commonly used in SCD, such as hydroxyurea. Rifampin, in particular, may reduce the efficacy of hydroxyurea, a drug critical for preventing sickle cell crises.
2. Prolonged treatment duration: Osteoarticular TB typically requires 9–12 months of therapy, compared to 6 months for pulmonary TB. This extended duration increases the risk of non-adherence and drug resistance.
3. Surgical considerations: In cases of extensive bone destruction or failure of medical therapy, surgical intervention—such as debridement or bone grafting—may be necessary. However, surgery in patients with SCD carries higher risks of complications, including wound healing issues and sickle cell crises.

A study on postoperative complications in patients with SCD undergoing hip replacement found that tuberculosis accounted for 12% of cases, with suppuration (pus formation) occurring in 6% of patients. This underscores the need for vigilant monitoring and tailored treatment plans in this population.

Key Takeaways for Clinicians and Patients

• Consider TB in the differential: In patients with SCD and chronic bone pain, especially with negative cultures for common pathogens, TB should be ruled out with PCR testing or bone biopsy.
• Imaging is not definitive: While X-rays and MRIs can suggest infection, they cannot distinguish between TB and other causes of osteomyelitis. Histopathology is essential.
• Multidisciplinary care is critical: Management should involve infectious disease specialists, hematologists, and orthopedic surgeons to balance anti-TB therapy with SCD-specific treatments.
• Preventive measures matter: Patients with SCD should be screened for latent TB, particularly if they live in or travel to endemic regions. Vaccination with Bacillus Calmette-Guérin (BCG) may offer some protection, though its efficacy in adults is limited.
• Patient education is key: Patients and caregivers should be aware of the signs of bone infections and the importance of early medical evaluation for persistent pain or swelling.

FAQ: Addressing Common Questions

1. How common is diaphyseal tuberculosis in sickle cell anemia?

Diaphyseal TB is extremely rare, even in patients with SCD. However, the immunocompromised state of SCD increases the risk of atypical infections, making it a diagnosis that should not be overlooked. The case report highlights the need for heightened clinical suspicion in this population.

2. What are the symptoms of diaphyseal tuberculosis?

Symptoms may include:

• Chronic, localized bone pain (often in the tibia, femur, or humerus)
• Swelling or tenderness over the affected bone
• Low-grade fever or night sweats
• Limited range of motion if the infection is near a joint
• Systemic symptoms like weight loss or fatigue (in advanced cases)

3. How is diaphyseal TB treated?

Treatment involves a prolonged course of anti-TB medications, typically for 9–12 months. The standard regimen includes:

• Initial phase (2 months): Isoniazid, rifampin, pyrazinamide, and ethambutol
• Continuation phase (7–10 months): Isoniazid and rifampin

Surgical intervention may be required for cases with extensive bone destruction or abscess formation.

4. Can diaphyseal TB be prevented?

Prevention strategies include:

• Screening for latent TB in high-risk patients (e.g., those with SCD living in endemic regions)
• Vaccination with BCG in childhood (though its efficacy wanes over time)
• Avoiding exposure to active TB cases
• Optimizing SCD management to reduce complications like avascular necrosis and immunosuppression

5. What is the prognosis for patients with diaphyseal TB and sickle cell anemia?

The prognosis depends on early diagnosis and adherence to treatment. Delayed diagnosis can lead to:

• Chronic osteomyelitis
• Pathological fractures
• Systemic spread of TB
• Permanent disability

With timely and appropriate treatment, many patients achieve full recovery, though long-term follow-up is essential to monitor for recurrence.

The Road Ahead: Research and Awareness

The intersection of sickle cell anemia and diaphyseal tuberculosis remains understudied, with most evidence coming from isolated case reports. Future research should focus on:

• Epidemiological studies: Determining the true prevalence of osteoarticular TB in patients with SCD, particularly in TB-endemic regions.
• Diagnostic advancements: Developing faster, more accurate tests for TB in bone samples, such as next-generation PCR or metagenomic sequencing.
• Treatment optimization: Identifying safer anti-TB regimens for patients with SCD, particularly those taking hydroxyurea or other disease-modifying therapies.
• Public health initiatives: Raising awareness among clinicians about the risk of atypical infections in SCD and improving access to diagnostic tools in resource-limited settings.

For patients with sickle cell anemia, the message is clear: persistent bone pain should never be dismissed as “just another crisis.” Early evaluation, including advanced imaging and targeted testing, can indicate the difference between a treatable infection and a lifelong disability. For clinicians, this case serves as a reminder that in medicine, the rarest diagnoses are often the most critical to consider.